Niagen Bioscience, Inc. - Common Stock (NAGE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
NAGE on Nasdaq
Shares outstanding
79,963,455
Price per share
$6.45
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
32,157,829
Total reported value
$204,621,568
% of total 13F portfolios
0%
Share change
+396,943
Value change
-$3,438,220
Number of holders
165
Price from insider filings
$6.45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Niagen Bioscience, Inc. - Common Stock (NAGE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 4.1% -19% $20,902,127 -$4,675,567 3,286,498 -18% The Vanguard Group 31 Dec 2025

As of 31 Dec 2025, 165 institutional investors reported holding 32,157,829 shares of Niagen Bioscience, Inc. - Common Stock (NAGE). This represents 40% of the company’s total 79,963,455 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Niagen Bioscience, Inc. - Common Stock (NAGE) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 5.1% 4,075,709 +2.5% 0% $25,921,508
VANGUARD GROUP INC 4.1% 3,286,498 -18% 0% $20,902,127
Tieton Capital Management, LLC 2.1% 1,645,093 -0.11% 3.6% $10,463,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2% 1,616,752 +13% 0.01% $10,282,543
UBS Group AG 1.8% 1,411,742 +18% 0% $8,978,679
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,294,863 -0.05% 0% $8,237,043
STATE STREET CORP 1.4% 1,091,039 -0.15% 0% $6,939,008
Qube Research & Technologies Ltd 1.3% 1,061,835 +21% 0.01% $6,753,271
GOLDMAN SACHS GROUP INC 1.2% 954,880 +152% 0% $6,073,037
DIMENSIONAL FUND ADVISORS LP 1.2% 920,370 +27% 0% $5,854,029
RENAISSANCE TECHNOLOGIES LLC 1.1% 914,118 +28% 0.01% $5,813,790
MORGAN STANLEY 1.1% 880,124 +67% 0% $5,597,587
AQR CAPITAL MANAGEMENT LLC 0.76% 605,954 +3.2% 0% $3,853,867
Connor, Clark & Lunn Investment Management Ltd. 0.73% 584,229 -7% 0.01% $3,715,696
ALGERT GLOBAL LLC 0.72% 573,276 +0.3% 0.06% $3,646,000
MILLENNIUM MANAGEMENT LLC 0.7% 561,110 -28% 0% $3,568,660
Nuveen, LLC 0.62% 491,962 -38% 0% $3,128,879
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.57% 459,445 -20% 0% $2,922,070
Trexquant Investment LP 0.55% 436,332 -1.4% 0.02% $2,775,072
NORTHERN TRUST CORP 0.54% 433,536 +0.42% 0% $2,757,289
JPMORGAN CHASE & CO 0.53% 426,384 +8.2% 0% $2,711,801
CITADEL ADVISORS LLC 0.49% 391,540 +96% 0% $2,490,194
AMERIPRISE FINANCIAL INC 0.49% 388,278 +1.3% 0% $2,469,448
SEI INVESTMENTS CO 0.48% 380,079 +1101% 0% $2,417,309
JANE STREET GROUP, LLC 0.45% 357,238 +126% 0% $2,272,034

Institutional Holders of Niagen Bioscience, Inc. - Common Stock (NAGE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 32,157,829 $204,621,568 -$3,438,220 $6.36 165
2025 Q3 31,740,712 $296,100,948 +$18,168,708 $9.33 160
2025 Q2 29,012,196 $417,768,625 +$66,370,280 $14.41 153
2025 Q1 24,896,783 $171,982,021 +$17,881,889 $6.90 138
2024 Q4 22,483,966 $119,285,057 +$25,349,283 $5.30 121
2024 Q3 17,622,945 $64,319,240 +$3,083,824 $3.65 89
2024 Q2 16,528,410 $45,123,441 +$8,628,734 $2.73 77
2024 Q1 13,127,574 $45,682,555 +$5,883,256 $3.48 65
2023 Q4 11,564,608 $16,537,741 +$369,862 $1.43 52
2023 Q3 11,213,819 $16,373,396 +$44,238 $1.46 54
2023 Q2 11,256,922 $17,672,233 -$922,792 $1.57 55
2023 Q1 11,852,869 $18,121,462 +$704,893 $1.53 57
2022 Q4 11,369,339 $19,098,682 -$446,189 $1.68 57
2022 Q3 12,230,830 $15,042,771 -$3,814,329 $1.23 57
2022 Q2 15,168,828 $25,334,849 -$9,375,811 $1.67 68
2022 Q1 20,302,888 $49,941,335 -$626,215 $2.46 80
2021 Q4 20,237,916 $75,894,369 -$3,740,099 $3.74 79
2021 Q3 20,510,161 $128,978,464 -$1,068,465 $6.27 83
2021 Q2 20,389,265 $201,000,146 -$22,216,215 $9.86 98
2021 Q1 22,588,375 $210,950,194 +$69,411,476 $9.34 94
2020 Q4 15,862,732 $76,145,799 +$2,886,275 $4.80 81
2020 Q3 15,297,870 $61,343,701 +$4,471,467 $4.01 73
2020 Q2 14,144,637 $64,936,694 +$6,481,014 $4.59 64
2020 Q1 12,769,825 $41,630,918 +$1,194,498 $3.26 59
2019 Q4 12,700,475 $54,741,949 +$1,963,390 $4.31 63
2019 Q3 11,578,983 $45,575,555 +$2,344,637 $3.94 59
2019 Q2 11,024,626 $51,238,233 +$4,983,621 $4.65 58
2019 Q1 10,070,082 $42,193,191 +$2,229,149 $4.19 58
2018 Q4 9,541,424 $32,736,941 -$393,980 $3.43 57
2018 Q3 9,540,520 $40,859,700 +$2,586,652 $4.29 64
2018 Q2 8,944,457 $33,186,100 +$8,097,974 $3.71 64
2018 Q1 6,602,351 $27,731,268 +$3,134,033 $4.20 57
2017 Q4 5,627,666 $33,094,575 +$14,019,072 $5.88 52
2017 Q3 3,291,658 $14,155,748 -$2,106,113 $4.30 40
2017 Q2 3,851,621 $14,711,031 -$3,742,492 $3.82 44
2017 Q1 5,045,065 $13,568,683 +$4,343,265 $2.69 45
2016 Q4 4,609,401 $15,256,781 +$829,481 $3.31 52
2016 Q3 4,376,691 $13,038,975 +$972,569 $2.98 48
2016 Q2 3,984,213 $16,491,977 +$16,477,977 $4.14 46
2016 Q1 10,000 $14,000 +$14,000 $1.40 1